|
Parameters
|
Tumor-infiltrating lymphocytes (n = 191)
|
|---|
|
Low (n = 96)
|
High (n = 95)
|
p value
|
|---|
|
Age (years)
|
|
≤ 45
|
31 (32.3%)
|
44 (46.3%)
|
0.047
|
|
> 60
|
65 (67.7%)
|
51 (53.7%)
|
|
Tumor size (mm)
|
|
≤ 20.0
|
20 (20.8%)
|
14 (14.7%)
|
0.271
|
|
> 20.0
|
76 (79.2%)
|
81 (85.3%)
|
|
Skin infiltration
|
|
Negative
|
71 (74.0%)
|
87 (91.6%)
|
0.001
|
|
Positive
|
25 (26.0%)
|
8 (8.4%)
|
|
Lymph node status
|
|
Negative
|
33 (34.4%)
|
39 (41.1%)
|
0.341
|
|
Positive
|
63 (65.6%)
|
56 (58.9%)
|
|
Estrogen receptor
|
|
Negative
|
37 (38.5%)
|
67 (70.5%)
|
< 0.001
|
|
Positive
|
59 (61.5%)
|
28 (29.5%)
|
|
Progesterone receptor
|
|
Negative
|
55 (57.3%)
|
76 (80.0%)
|
0.001
|
|
Positive
|
41 (42.7%)
|
19 (20.0%)
|
|
Hormone receptor
|
|
Negative
|
35 (36.5%)
|
66 (69.5%)
|
< 0.001
|
|
Positive
|
61 (63.5%)
|
29 (30.5%)
|
|
HER2
|
|
Negative
|
69 (71.9%)
|
47 (49.5%)
|
0.002
|
|
Positive
|
27 (28.1%)
|
48 (50.5%)
|
|
Ki67
|
|
≤ 14%
|
37 (38.5%)
|
25 (26.3%)
|
0.071
|
|
> 14%
|
59 (61.5%)
|
70 (73.7%)
|
|
ORR
|
|
Non-responders
|
18 (18.8%)
|
4 (4.2%)
|
0.002
|
|
Responders
|
78 (81.2%)
|
91 (95.8%)
|
|
Pathological response
|
|
Non-pCR
|
79 (82.3%)
|
45 (47.4%)
|
< 0.001
|
|
pCR
|
17 (17.7%)
|
50 (52.6%)
|
- TILs tumor-infiltrating lymphocytes HER, human epidermal growth factor receptor, ORR objective response rate, CR complete response
